FY2025 · ended Dec 31, 2025 · Revenue $1.90M, +485.8% YoY · Filed Mar 27, 2026
Bio Essence Corp. (BIOE) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.9 million and net income of $896,197. As of Jun 30, 2026 it held $675 in cash and investments and $1.6 million in total debt.
Revenue (TTM)
$2.91M
+416.6% vs year-ago TTM
Net income (TTM)
$1.52M
+210.5% vs year-ago TTM
Operating cash flow (TTM)
$1.08M
+16.7% vs year-ago TTM
Free cash flow
$-1.03M
+27.2% vs prior year
EPS
$-0.03
+0.0% vs prior year
Dividend per share
None
Shares outstanding
38.01M
+0.0% vs prior year
Net cash
$-1.56M
as of Jun 30, 2026
Operating margin
52.9%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BIOE (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- CA
- Headquarters
- Irvine, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1723059
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.9M | $323,940 | $551,506 | $621,590 | $887,984 |
| Operating income | $900,011 | -$459,438 | -$345,590 | -$511,138 | -$857,527 |
| Net income | $896,197 | -$1.3M | -$971,879 | -$809,679 | -$647,564 |
| Diluted EPS | — | -$0.03 | -$0.03 | -$0.02 | — |
| Operating cash flow | $1.6M | $623,865 | -$1.0M | -$703,241 | -$1.3M |
| Free cash flow | — | — | -$1.0M | — | -$1.4M |
| Total assets | $422,474 | $281,024 | $2.8M | $1.5M | $1.7M |
| Total liabilities | $2.5M | $3.3M | $4.4M | $4.8M | $4.1M |
| Stockholders' equity | -$2.1M | -$3.0M | -$1.7M | -$3.2M | -$2.4M |
| Cash and investments | — | $1,371 | $114 | $6,262 | $303 |
| Total debt | $1.6M | $1.5M | $1.4M | $1.1M | $1.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change
|
Oct 23, 2026 | Oct 15, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K/A |
Amended current report
Material agreement
|
May 19, 2026 | Apr 24, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement
|
Apr 24, 2026 | Apr 24, 2026 |
| 10-K | Annual report | Mar 27, 2026 | Dec 31, 2025 |
All 87 Bio Essence Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.